FY2025 · ended Dec 31, 2025 · Revenue $10.22M · Filed Mar 31, 2026
Alpha Cognition Inc. (ACOG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $10.2 million and a net loss of $20.7 million. Free cash flow was -$20.7 million.
Revenue (TTM)
$15.26M
Net income (TTM)
$-21.01M
+7.0% vs year-ago TTM
Operating cash flow (TTM)
$-30.85M
-155.7% vs year-ago TTM
Free cash flow (TTM)
$-31.18M
EPS (TTM)
$-1.02
+44.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
21.77M
+35.9% vs prior year
Net cash
—
Operating margin
-174.7%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ACOG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Grapevine, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1655923
- Former names
- Neurodyn Cognition Inc. (until Oct 9, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $10.2M | — |
| Operating income | -$22.7M | -$12.0M |
| Net income | -$20.7M | -$14.8M |
| Diluted EPS | -$1.18 | -$2.04 |
| Operating cash flow | -$20.4M | -$7.8M |
| Free cash flow | -$20.7M | -$7.8M |
| Total assets | $79.7M | $50.7M |
| Total liabilities | $17.2M | $11.6M |
| Stockholders' equity | $62.5M | $39.1M |
| Cash and investments | $66.0M | $48.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
May 1, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 20, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 14, 2026 | Apr 10, 2026 |
All 216 Alpha Cognition Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.